AGIHO guideline on evidence-based management of COVID-19 in cancer patients: 2022 update on vaccination, pharmacological prophylaxis and therapy in light of the omicron variants-Reference-Cited by-同舟云学术

AGIHO guideline on evidence-based management of COVID-19 in cancer patients: 2022 update on vaccination, pharmacological prophylaxis and therapy in light of the omicron variants

Published:2023-03 Issue: Volume:181 Page:102-118
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Giesen Nicola^ORCID,Busch Elena,Schalk Enrico^ORCID,Beutel Gernot,Rüthrich Maria M.,Hentrich Marcus,Hertenstein Bernd,Hirsch Hans H.,Karthaus Meinolf,Khodamoradi Yascha^ORCID,Koehler Philipp,Krüger William,Koldehoff Michael^ORCID,Krause Robert,Mellinghoff Sibylle C.,Penack Olaf,Sandherr Michael,Seggewiss-Bernhardt Ruth^ORCID,Spiekermann Karsten,Sprute Rosanne^ORCID,Stemler Jannik,Weissinger Florian,Wörmann Bernhard,Wolf Hans-Heinrich,Cornely Oliver A.^ORCID,Rieger Christina T.,von Lilienfeld-Toal Marie

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference149 articles.

1. Clinical characteristics of coronavirus disease 2019 in China;Guan;N Engl J Med,2020

2. A novel coronavirus from patients with pneumonia in China, 2019;Zhu;N Engl J Med,2020

3. COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA);Pagano;J Hematol Oncol,2021

4. COVID-19 in cancer patients: clinical characteristics and outcome-an analysis of the LEOSS registry;Ruthrich;Ann Hematol,2021

5. COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study;Lee;Lancet Oncol,2020

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Managing and treating COVID-19 in patients with hematological malignancies: a narrative review and expert insights;Clinical and Experimental Medicine;2024-06-04

2. New variants of COVID‐19 (XBB.1.5 and XBB.1.16, the “Arcturus”): A review of highly questioned concerns, a brief comparison between different peaks in the COVID‐19 pandemic, with a focused systematic review on expert recommendations for prevention, vaccination, and treatment measures in the general population and at‐risk groups;Immunity, Inflammation and Disease;2024-06

3. Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022;eClinicalMedicine;2024-05

4. COVID-19 in cancer patients: patient characteristics and outcomes in the post-COVID-19 vaccination period;Turkish Journal of Medical Sciences;2023-12-12

5. Reduced prophylactic effect of tixagevimab–cilgavimab in patients with hematological malignancies and without antibody response after SARS‐COV‐2 vaccination;European Journal of Haematology;2023-07-18